Oxford Nanopore Technologies Ltd

MinION is a pocket-sized portable device used for real-time biological analysis. It is adaptable to the analysis of DNA, RNA, or proteins. MinION's simple workflow allows end-to-end experiments in many environments.

Start using MinION

PromethION combines MinION's simplicity of use with greater workflow flexibility through scale and a modular design. Increase throughput by analysing the same sample simultaneously in multiple flow cells, or run different samples concurrently.

The GridION system, currently in development, is a scalable real-time analysis system designed to analyse single molecules such as DNA, RNA and proteins.

Metrichor provides a cloud-based platform for real time analysis of data from nanopore devices. Applications available through Metrichor will expand with the ultimate goal of enabling the analysis of any living thing, by any user, in any environment.

Start using MinION

Executive - Zoe McDougall
Zoe McDougall
Corporate and Communications Director
go back

Zoe has extensive experience in marketing, corporate and investor communications in the science and healthcare sector. Zoe joined Oxford Nanopore in January 2008, bringing expertise in pre-marketing of products, building and management of corporate reputation, IR and fundraising. At Oxford Nanopore Zoe works with the executive and management teams to ensure that the business development plan is supported by strategic serving of investor, customer and other stakeholder relationships. She also works on the fundraisings that have so far raised £74 million.

Zoe gained a BSc in Physiology, specialising in electrophysiology and neurophysiology, at the University of Bristol. The first years of her career were spent with SmithKline Beecham, working in sales and marketing. Zoe then joined Porter Novelli, where she consulted on marketing communications and issues management for companies including Glaxo Wellcome, Novartis and Bristol-Myers Squibb and conducted award-winning work on the blood products/ nvCJD issue for BPL, part of the National Blood Service.

At specialty pharmaceutical company Sinclair Pharmaceuticals, Zoe played an integral role in the £60m IPO and headed subsequent corporate and investor communications. In 2005, Zoe worked with a Sri Lankan humanitarian organization to create and manage a mobile medical unit, serving populations displaced by the Asian tsunami and civil unrest